Archives: Speakers

As the Chief Information Security Officer (CISO) at Natera, Dr. Bill Chen is responsible for managing an enterprise-wide cybersecurity program that encompasses strategic, governance, risk and compliance (GRC), data protection, product security, and privacy engineering. Prior to joining Natera, he held different executive and technical positions at VISA, Palo Alto Networks, Cisco, Microsoft, and Coupang. With over two decades of experience in cybersecurity, he is also a successful start-ups advisor, a public speaker, and an author with multiple publications and patents. In his spare time, he plays guitar and enjoys the outdoors.

Priya Ryali, MBA, brings over 18+ years of experience in biopharmaceutical research and development. She is currently Head of Clinical Operations at ReCode Therapeutics focused on rare disease drug development in Primary Ciliary Dyskinesia and Cystic Fibrosis.

Previously she was Director of Clinical Operations at Alector, where she focused on leading the company’s marquee program in Alzheimer’s Disease. Before joining Alector, Priya worked on rare disease programs at Denali, in an early-phase neuro pediatric program for MPS II (Hunter Syndrome), at Ultragenyx, leading the company’s Disease Monitoring Program for one of its first marketed products, and at Crysvita for treatment of XLH, a rare bone disease in pediatrics and adults. Priya began her work in clinical operations in Janssen Alzheimer’s Immunotherapy and at Gilead, where she worked on late-phase HIV programs, including Biktarvy and Genvoya. She started in the industry doing bench research in early lead discovery at Amgen. Priya holds a BS in biotechnology from the University of California, Davis, and an MBA from Santa Clara University.

Jane is a clinical research change agent with molecule development success in both global and start up biotechnology/ pharmaceutical companies. She have extensive experience leading global teams through changing business, technical, regulatory and competitive needs. Clinical Operations and DCT design /. execution is her expertise, from due diligence and protocol design through study conduct, regulatory submission and approval. In recent roles, she has lead teams to solve how technology can support clinical trial objectives and patient access. Technology, data assets and patient behaviors have evolved, and so has my focus. A passion for driving patient and site-friendly approaches to clinical trials, creating efficiency and speed along with a great customer experience. A unique strength in finding the fit between innovative solutions and development team needs.
My core competencies include:
• Innovation • Leadership • Patient-Centricity • Technology Scale and Deployment
• Project Management •Strategic Planning •Data-driven Execution
• Process Improvement • People Development •Building and Leading Teams

Kim Erby is Director of Clinical Operations at Cytokinetics, Inc. where she oversees the Cardiovascular program for obstructive hypertrophic cardiomyopathy (oHCM) and other CV pipeline products.  Kim has been in the research industry for 25+ years and has worked in the areas of heart failure, hepatitis B and vaccine development, ophthalmology, and oncology.  She is passionate about conducting quality research while making a difference for patients and has been fortunate to see several products come to market from Phase 1 to FDA approval.  She grew up in Cincinnati, OH and has been living in the San Francisco Bay Area since graduating from Stanford University. 

Kimberly Barnholt has been a healthcare leader in various roles spanning from academic research, to disruptive start-up, to global pharmaceutical company. In all roles, she has focused on bridging science, data, and operational disciplines to challenge the status quo and transform how we can deliver more impact for our patients. At Genentech, she has served as a Program Leader for cross-industry collaborations and cross-R&D data ecosystem transformation. Currently, Dr. Barnholt is leading an Evidence Generation team of data strategists and clinical innovation and technology leaders to integrate new approaches to clinical trials.